Progress in the treatment of PCNSL. Comparison of outcomes for newly diagnosed PCNSL in 2 multicenter cooperative group clinical trials. (A) Combined modality therapy with whole-brain radiotherapy in RTOG-9310 resulted in median progression-free survival of 2 years, with a significant rate of disease progression beyond 2 years. (B) Immunochemotherapy with rituximab plus intensive consolidation—CALGB (Alliance) 50202—resulted in a median progression-free survival of 4 years with evidence for a stable plateau in the survival curve. (C) Progression-free survival was particularly encouraging for the 65% of patients who received both induction plus consolidation treatment modules of CALGB (Alliance) 50202.